What is InDevR?
Based in Boulder, CO, InDevR is a biotechnology company dedicated to enhancing vaccine process optimization and manufacturing through advanced protein characterization tools. The company has a proven track record, having launched several successful life science tool product lines that support vaccine development and serological research. In addition to its product offerings, InDevR provides specialized testing and custom services tailored for biotherapeutic companies, positioning itself as a comprehensive partner in the biopharmaceutical ecosystem.
How much funding has InDevR raised?
InDevR has raised a total of $19.3M across 4 funding rounds:
Grant
$2.9M
Series A
$7M
Debt
$350K
Series B
$9M
Grant (2014): $2.9M with participation from National Institute of Allergy and Infectious Diseases
Series A (2019): $7M led by Adjuvant Capital
Debt (2020): $350K supported by PPP
Series B (2023): $9M featuring BioMérieux Turkey and Adjuvant Capital
Key Investors in InDevR
National Institute of Allergy and Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID), operating under the NIH, is a leading supporter of biomedical research focused on infectious and immunologic diseases. Their involvement suggests a strong alignment with InDevR's mission in vaccine development and public health.
Adjuvant Capital
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges. The company invests in areas such as infectious diseases, maternal and child health, and nutrition, aiming to make impactful medical innovations accessible to underserved populations.
BioMérieux Turkey
BioMérieux is a global leader in in vitro diagnostics and industrial microbiology, with a significant presence in Turkey. Their participation in InDevR's funding round indicates a strategic interest in complementary technologies within the diagnostics and bioprocessing sectors.
What's next for InDevR?
With the recent major strategic investment and a substantial overall funding base of $19.3M, InDevR is well-positioned for its next phase of expansion. The company's focus on critical areas like vaccine development and manufacturing optimization, coupled with its established product lines and service offerings, suggests a strategic direction towards scaling operations and potentially broadening its technological applications. Future growth may involve further product innovation, strategic partnerships, or market penetration into new therapeutic areas, leveraging its strong foundation in protein characterization and bioprocess support.
See full InDevR company page
